CD8 (cluster of differentiation 8)

Incorporating aCAF status modestly but consistently improved survival prediction in machine learning-based prognostic models. Histologically identifiable aCAFs on routine H&E slides represent a clinically accessible prognostic biomarker in diffuse-subtype GC, highlighting the importance of stromal morphology in risk stratification and providing a translational framework for future therapeutic studies targeting the tumor microenvironment.

Peripheral blood from 34 NSCLC patients treated with nivolumab monotherapy was collected at three time points (baseline, week 2 and 4, i.e. TP1, TP2 and TP3)...Moreover, potential dynamic biomarkers to assess prognosis during ICB therapy in NSCLC were identified, including changes in NLR, CD8+ T cells and CD11c+ eosinophils. This provides a foundation for further research, emphasizing validation of the pipeline and biomarkers in larger, diverse cohorts and independent datasets to assess robustness and generalizability.

Generally, WNT10A promotes LUAD progression and CD8 + T cell dysfunction through FRAT1-mediated Wnt signaling and CXCL12 activation. Focusing on WNT10A could offer a compelling approach to boosting T cell-driven anti-tumor responses for the treatment of LUAD.

This work redefines tumor organoids as immunotherapeutic materials and establishes a rapid, cost-effective platform for personalized T cell manufacturing. Our findings provide a new translational route for adoptive cell therapy in solid tumors using patient-derived materials.

They show that invasive fronts with high epithelial-mesenchymal transition (EMT) activity co-localize with myeloid and regulatory T-cell niches dominated by IL-1β, NF-κB, IL-10, STAT3, and TGF-β, along with exhausted CD8+ T cells, thereby promoting immune escape and invasion. Integrating these layers yields mechanism-based biomarkers and therapeutic nodes for risk-adapted precision treatment.

We developed a biologically interpretable EMT-based prognostic model that stratifies survival and reflects immune-microenvironment heterogeneity in LUSC. Larger, stage-balanced and immunotherapy-treated cohorts are needed to further validate its clinical utility.

The median OS from diagnosis (OS1) was 19.1 months (95% CI: 13.6-35.1), and the median OS from the diagnosis of brain metastases (OS2) was 11.35 months. The brain TME demonstrates varying levels of TIL and immune checkpoint expression, highlighting the need for further research to develop effective therapies for intracranial metastases.

Pharmacogenomic analyses suggested distinct drug sensitivity patterns in BDKRB1-high tumors and identified fasudil as a potential candidate compound for reversing BDKRB1-associated transcriptional signatures. This integrative analysis identifies BDKRB1 as a microenvironment-associated marker linking genomic instability with inflammatory and immunosuppressive tumor ecosystems in ovarian cancer. Although the findings are primarily associative, they provide a systems-level perspective on immune evasion mechanisms and highlight BDKRB1 as a potential biomarker for TME characterization and therapeutic hypothesis generation.

Furthermore, treated animals displayed higher absolute numbers of CD4+ and CD8+ T cells producing IFN-γ and TNF-α, particularly after anti-CD3 stimulation. Treatment with β-GESc demonstrates immunomodulatory potential by increasing both splenic and systemic cell frequencies, contributing to the control of experimental melanoma.

Unipolar nanosecond pulses showed a clearer increase in central memory T-cell populations, while bipolar pulses were associated with pronounced modulation of lymph-node immune composition. It is shown that bipolar cancellation phenomenon is not necessarily triggered in vivo, which was predicted by in vitro data.

This study presents octopus-inspired engineered bacteria with a "plug-and-display" system and tumor-specific drug delivery that achieves enhanced tumor targeting and potent antitumor effects. This study describes a promising strategy for the precise and safe clinical translation of bacteria-mediated cancer immunotherapy.

Serving as a bridge to clinical translation, YBX1 effectively predicted clinical responses in three immunotherapy cohorts and demonstrated broad resistance to 12 chemotherapeutic and targeted agents. Our multiomics integration pipeline highlights YBX1 as a dual-functional oncogene that couples malignant proliferation with immune evasion, establishing it as a highly translational biomarker and an actionable target for precision PRAD management.